Barrett's esophagus: proton pump inhibitors and chemoprevention I
- Resource Type
- Authors
- George, Triadafilopoulos; Antonio, Taddei; Paolo, Bechi; Giancarlo, Freschi; Maria Novella, Ringressi; Duccio Rossi, Degli'Innocenti; Francesca, Castiglione; Emmanuella, Masini; Marek, Majewski; Grzegorz, Wallner; Jerzy, Sarosiek; John F, Dillon; Richard C, McCallum; Katerina, Dvorak; Aaron, Goldman; Philip, Woodland; Daniel, Sifrim; Joel E, Richter; Michael, Vieth; Helmut, Neumann; Cord, Langner; Norihisa, Ishimura; Yuji, Amano; Valter Nilton, Felix
- Source
- Subject
- Barrett Esophagus
drug therapy/pathology/prevention /&/ control, Chemoprevention, Humans, Proton Pump Inhibitors
therapeutic use
Humans
Proton Pump Inhibitors
Chemoprevention
- Language
The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.